Finasteride can be combined with alpha-blockers (e.g., tamsulosin) to improve urinary symptoms. The combination is frequently used, but a prescriber should review potential additive effects on blood pressure and monitor for side effects.
Yes. Finasteride reduces PSA levels by roughly half. Clinicians usually double the measured PSA value to obtain a corrected estimate when evaluating prostate health.
Fincar tablets may be carried in hand luggage or checked baggage. Keep them in the original labeled container, and bring a copy of the prescription if traveling internationally, as some countries require documentation for prescription medicines.
Persistent symptoms, sometimes referred to as post-finasteride syndrome, are rare but reported. Report the issue to a healthcare professional for assessment; they may refer you to a specialist for further evaluation.
Finasteride lowers DHT but does not significantly alter total testosterone levels. It can be used alongside testosterone replacement therapy, but clinicians should monitor PSA and symptom response.
Finasteride tablets are designed for oral ingestion whole. Crushing or splitting the tablet may affect drug release and dose accuracy. Only split the tablet under medical advice when a lower dose is required.
No specific foods are known to interfere with finasteride absorption. However, maintaining a balanced diet supports overall prostate health and can help mitigate urinary symptoms.
Patients often notice improvement within 3-6 months of consistent daily dosing, though maximum benefit may take up to a year. Ongoing assessment helps determine whether therapy should be continued.
Finasteride reduces DHT, which can theoretically influence hair growth patterns. Unintended hair growth is uncommon, but any new or altered hair growth should be discussed with a clinician.
Do not flush tablets down the toilet. Use a pharmacy-based medication take-back service or follow local hazardous-waste guidelines to prevent environmental contamination.
Fincar is a prescription medication that contains finasteride as its sole active ingredient. It is formulated as a 5 mg oral pill and belongs to the men’s health therapeutic category. Finasteride is a 5α-reductase inhibitor that reduces the conversion of testosterone to dihydrotestosterone (DHT). In the United Kingdom, Fincar is classified as a prescription-only medicine (POM) and is regulated by the Medicines and Healthcare products Regulatory Agency (MHRA). The product is marketed by an unnamed pharmaceutical company; specific manufacturer details are not required for patient-focused education.
Finasteride blocks the type II isoenzyme of 5α-reducing enzyme. By inhibiting this enzyme, the drug lowers DHT levels in the prostate, serum, and scalp. DHT is a potent androgen that drives prostate growth and contributes to hair-follicle miniaturisation. Reducing DHT leads to:
The onset of clinical benefit for BPH typically appears after several weeks of continuous therapy, with peak effect reached after about six months. Finasteride has a high oral bioavailability (≈ 65 %) and is extensively metabolised in the liver, producing an active metabolite that contributes to its therapeutic effect. The drug’s half-life is approximately 6-8 hours, but its pharmacodynamic effect on DHT persists for several days after dosing.
Finasteride is not approved for use in women, children, or adolescents.
Finasteride at a 1 mg daily dose is licensed for androgenetic alopecia. Some clinicians prescribe the 5 mg tablet off-label for the same condition, splitting the tablet to achieve a lower dose. Clinical studies have demonstrated that finasteride reduces scalp DHT by over 60 % and can increase hair count in treated areas.
Regulatory status: Off-label for hair loss; not approved at the 5 mg strength for this use in the UK.
Disclaimer: Off-label use requires supervision by a qualified healthcare professional, who will assess individual risk-benefit factors.
These effects are usually mild and may improve with continued therapy.
Note: Patients should disclose all medicines, over-the-counter products, supplements, and herbal preparations to their prescriber before starting Fincar.
This article provides educational information about Fincar and is not a substitute for professional medical advice. Treatment decisions, including the use of any medication for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes only and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
